International Journal of Hematology

, Volume 84, Issue 5, pp 406–412

Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan: A Questionnaire-Based Report from the “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology

  • Akihiko Gotoh
  • Kazuma Ohyashiki
  • Kazuo Oshimi
  • Noriko Usui
  • Tomomitsu Hotta
  • Kazuo Dan
  • Yasuo Ikeda
Article

Abstract

Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma. Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan. Because bortezomib has not yet been approved for general use in Japan and is imported by attending physicians on the request of patients, The Japanese Society of Hematology and The Japanese Society of Clinical Hematology sent urgent questionnaires to the councilors of both societies to explore the situation and the details of pulmonary complications associated with bortezomib therapy. Clinical details were available for 46 patients who had been treated with personally imported bortezomib in Japan. Seven patients (15.2%), including 3 who died from respiratory failure, showed complications definitely or probably caused by bortezomib. Of the 7 patients, 6 had a prior history of stem cell transplantation (SCT), whereas only 14 of 39 patients without lung injury had received SCT treatment (P = .033, Fisher exact test). Multivariate analysis revealed that the concomitant use of corticosteroids might reduce the risk of lung injury (P = .024; odds ratio, 0.055) and that a previous SCT might increase the risk (P = .042; odds ratio, 13.140).We summarized these data from questionnaires for a limited Japanese cohort and therefore do not know the precise incidence of lung injury linked to fatal progression. Thus, future verification concerning this matter is warranted after the approval of bortezomib for use in Japan. Clinicians should be aware of the possibility of severe pulmonary complications associated with bortezomib therapy.

Key words

Bortezomib Lung injury Stem cell transplantation Corticosteroid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bross PF, Kane R, Farrell AT, et al. Approval summary for borte-zomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954–3964.CrossRefPubMedGoogle Scholar
  2. 2.
    Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–783.CrossRefPubMedGoogle Scholar
  3. 3.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617.CrossRefPubMedGoogle Scholar
  4. 4.
    Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172.CrossRefPubMedGoogle Scholar
  5. 5.
    Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492–3494.CrossRefPubMedGoogle Scholar
  6. 6.
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498.CrossRefPubMedGoogle Scholar
  7. 7.
    Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28:103–113.CrossRefPubMedGoogle Scholar
  8. 8.
    Inokuma S, Sakata M, Yoshida A, Shiratori K, Kiyosawa H. Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol. 1996;23:1282–1285.PubMedGoogle Scholar
  9. 9.
    Kamata Y, Anara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med. 2004;43:1201–1204.CrossRefPubMedGoogle Scholar
  10. 10.
    Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006;22:561–573.CrossRefPubMedGoogle Scholar
  11. 11.
    Verleden GM, du Bois RM, Bouros D, et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J. 2001;32(suppl):17s-29s.Google Scholar
  12. 12.
    Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005;45:465–476.CrossRefPubMedGoogle Scholar
  13. 13.
    Everhart MB, Han W, Sherrill TP, et al. Duration and intensity of NF-κB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006;176:4995–5005.PubMedGoogle Scholar
  14. 14.
    Tian XF, Yao JH, Li YH, et al. Effect of nuclear factor kappa B on intercellular adhesion molecule-1 expression and neutrophil infiltration in lung injury induced by intestinal ischemia/reperfusion in rats. World J Gastroenterol. 2006;12:388–392.PubMedGoogle Scholar
  15. 15.
    Yang G, Abate A, George AG, Weng YH, Dennery PA. Maturational differences in lung NF-κB activation and their role in tolerance to hyperoxia. J Clin Invest. 2004;114:669–678.PubMedGoogle Scholar
  16. 16.
    Franek WR, Morrow DM, Zhu H, et al. NF-κB protects lung epithelium against hyperoxia-induced nonapoptotic cell death-oncosis. Free Radic Biol Med. 2004;37:1670–1679.CrossRefPubMedGoogle Scholar
  17. 17.
    Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–762.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Akihiko Gotoh
    • 1
  • Kazuma Ohyashiki
    • 1
  • Kazuo Oshimi
    • 1
  • Noriko Usui
    • 1
  • Tomomitsu Hotta
    • 1
  • Kazuo Dan
    • 1
  • Yasuo Ikeda
    • 1
  1. 1.The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical HematologyJapan
  2. 2.First Department of Internal Medicine (Hematology Division)Tokyo Medical UniversityTokyoJapan

Personalised recommendations